medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 6

Next >>

Gac Med Mex 2003; 139 (6)

Effects of Cisplatin on Auditory Function in Children with Cancer. Otoacoustic Emission Evaluation

Toral-Martiñón R, Poblano A, Collado-Corona MA, González R

Language: Spanish
References: 31
Page: 529-534
PDF size: 1405.67 Kb.


ABSTRACT

This study was done to ascertain prospectively whether distortion product-evoked otoacoustic emissions (DP-EOAE) might detect changes in specific frequencies damaged in inner ear function earlier, before they become permanent after cisplatinum exposure for cancer treatment in children. Sixteen children treated with cisplatinum for various types of cancer were repeatedly evaluated after each chemotherapy session; results were compared to 44 controls. We observed a progressive damage in auditory function. In second assessment 50% of DP-EOAE studies were abnormal; in the third study, 66% were abnormal, and in the fourth test 71% were abnormal. Our results suggest that DP-EOAE are useful tests for search earlier auditory changes induced by cisplatinum therapy; for higher frequencies are the most affected, and we propose that DP-EOAE be a mandatory test before treatment and during cisplatinum therapy to detect or diagnose early hearing loss.


REFERENCES

  1. Kaye SB, Cassidy PJ, Lewis CR, Duncan ID, Gordon HK, Kichener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Ramkin EM, Davis JA, Reed NS, Crawford SM, MacLean SM, Parkin D, Sarkar TK, Kennedy J, Symonds RP. Scottish Gynecology Cancer Trials Group. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:2113.

  2. 2. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ. Intraperitoneal cisplatin plus intravenous cyclophosphamide for stage II ovarian cancer. New Engl J Med 1996;335:1950.

  3. 3. Rivera-Luna R, Leal-Leal C, Cárdenas-Cardos R, Martínez-Avalos A, Meza-Coria C, Navarro-Alegría I, Ruano-Aguilar J. A survey of 4,876 children with cancer. Certain epidemiologic aspects from a single institution. Bol Med Hosp Inf Mex 1996;53:598.

  4. 4. Fajardo-Gutiérrez A, Mejía-Aranguré M, Gómez-Delgado A, Mendoza-Sánchez H, Garduño-Espinoza J, Martínez-García MC. Epidemiología de las neoplasias malignas en niños residentes del Distrito Federeal. Bol Med Hosp Inf Mex 1995;52:507.

  5. 5. Strauss M, Towfighi J, Lord S, Lipton A, Harvey HA, Brown B. Cisplatinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope 1983;93:1554.

  6. 6. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Prichard J. Cisplatinum ototoxicity in children: A practical grading system. 1991;19:295.

  7. 7. Skinner R, Pearson ADJ, Amineddine HA, Mathias DB, Craft AW. Otoxicity of cisplatinum in children and adolescents. Br J Cancer 1990;61:927.

  8. 8. Sie K, Norton S. Changes in otoacustic emissions and auditory brain stem response after cis-platinum exposure in gerbils. Otolaryngol Head Neck Surg 1997;116:585.

  9. 9. Hoistad DL, Ondrey FG, Mutlu C, Schachern PA, Paparella MM, Adams GL. Histopathology of human temporal bone after cis-platinum, radiation, or both. Otolaryngol Head Neck Surg 1998;118:825.

  10. Kemp DT. Stimulated acoustic emisions from within the human auditory system. J Acoust Soc Am 1978;64:1386-1391.

  11. Probst R, harris FP, Hauser R. Clinical monitoring using otoacustic emissions. Br J Audiol 1993;27:85.

  12. Toral-Martiñon R. Emisiones otoacusticas uso en el estudio de la audición y en condiciones de la hipoacusia en el niño. In: Hernández OF, Flores RT, Peñaloza LY. editirs. Registros electrofisiológicos para el diagnóstico de la patología de la comunicación humana. SSa-INCH. 1997. p. 297.

  13. Tanaka Y, O-Uchi T, Arai Y, Suzuki J. Otoacoustic emission as an indicator in evaluating inner ear impairments. Acta Otolaryngol (stockh) 1987;103:644.

  14. Bonfils P, Dumont A, Marie P, Francois M, Narcy P. Evoked otoacustic emissions in new-born hearing screening. Laryngoscope 1990;100:186.

  15. Chuang SW, Gerber SE, Throton ARD. Evoked acoustic emissions in preterm infants. Int J Pediatr Otorhynolaryngol 1993;26:39.

  16. Nelson D, Kimberley B. Distortion products emissions and auditory sensitivity in human ears with normal hearing and cochlear hearing loss. J Speech Hear Res 1992;35:1142.

  17. Francois M, Laccourreye L, Tran Ba Huy E, Narcy P. Hearing impairment in infants after meningitis: detection by transient evoked otoacustic emissions. J Pediatr 1997;130:712.

  18. Poblano A, Flores RT, Elías CY, Ríos VA, Llano G. Emisiones otoacústicas-producto de la distorsión en prescolares. Valores normativos. Bol Med Hosp Inf Mex 1996;53:310.

  19. McHaney VA, Thibadoux MA. Hearing loss in children and CDDP. J Pediatr 1983;102:314.

  20. Marco-Algarra J, Basterra J, Marco J. Cis-diaminedichloro platinum ototoxicity. An experimental study. Acta Otolaryngol (Stockh) 1985;99:343.

  21. McAlpine D, Johnstone BMT. The ototoxic mechanism of cisplatinum: Hear Res 1990;47:191.

  22. Kimitsuki T, Nagaka T, Hisashi K, Komiya S. Cisplatinum block mechano-electric trasducer current in chick cochlear hair cells. Hear Res 1993;71:64.

  23. Hawkins JE. Comparative pathology: aging, noise, and ototoxic drugs. Adv Otorhinolaryngol 1973;20:125.

  24. Thalman R, Kusakari J, Miyoshi T. Dysfunctions of energy releasing and consuming process of the cochlea. Laryngoscope 1973;83:1690.

  25. Fausti SA, Schechter MA, Rappaport BZ, Frey RH, Mass RE. Early detection of cisplatinum ototoxicity. Cancer 1984;53:224.

  26. Pollera CF, Marolla P, Nardi M, Ameglio F, Cozzo L, Beberé F. Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long term effects. Cancer Chemother Pharmacol 1988;21:61.

  27. Stavroulaki P, Apostolopoulous N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001; 59(1):47-57.

  28. Berg AL, Spitzer JB, Garvin JH. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope 1999;109(11):1806-14.

  29. Yardley MP, Davies CM, Stevens JC. Use of transient evoked otoacoustic emissions to detect and monitor cochear damage caused by platinum-containing drugs. Br J Audiol 1998; 32(5):305-16.

  30. Allen GC, Tiu C, Koike K, Ritchey AK, Kurs-Lasky M, Wax MK. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaringol Head Neck Surg 1998; 118(5): 584-8

  31. Sie KC, Norton SJ. Changes in otoacoustic emissions and auditory brain stem response after cis-platinum exposure in gerbils. otolaryngol Head Neck Surg . 1997;116(6Pt1):585-92.




2020     |     www.medigraphic.com